Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.

Ninomiya K, Ichihara E, Hotta K, Sone N, Murakami T, Harada D, Oze I, Kubo T, Tanaka H, Kuyama S, Kishino D, Bessho A, Harita S, Katsui K, Tanimoto M, Kiura K.

Clin Lung Cancer. 2017 Mar;18(2):245-249. doi: 10.1016/j.cllc.2016.08.001. Epub 2016 Oct 19.

PMID:
27847247
2.

Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.

Mehmood Q, Sun A, Becker N, Higgins J, Marshall A, Le LW, Vines DC, McCloskey P, Ford V, Clarke K, Yap M, Bezjak A, Bissonnette JP.

J Thorac Oncol. 2016 Feb;11(2):213-21. doi: 10.1016/j.jtho.2015.10.006. Epub 2015 Dec 22.

3.

Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.

Bar-Ad V, Leiby B, Witek M, Xiao Y, Cui Y, Dai Y, Cao J, Axelrod R, Campling B, Both S, Werner-Wasik M.

Am J Clin Oncol. 2014 Oct;37(5):433-7. doi: 10.1097/COC.0b013e31827de7a2.

PMID:
23388558
4.

Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer.

Kuroda Y, Sekine I, Sumi M, Sekii S, Takahashi K, Inaba K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Murakami N, Morota M, Mayahara H, Ito Y, Tamura T, Nemoto K, Itami J.

Technol Cancer Res Treat. 2013 Aug;12(4):333-9. doi: 10.7785/tcrt.2012.500319. Epub 2013 Jan 25.

PMID:
23369154
5.

An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.

Ma L, Qiu B, Li Q, Chen L, Wang B, Hu Y, Liu M, Zhang L, Huang Y, Deng X, Xia Y, Lin M, Liu H.

Radiat Oncol. 2018 Jul 17;13(1):130. doi: 10.1186/s13014-018-1073-3.

6.

Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U.

J Thorac Oncol. 2014 Jun;9(6):825-33. doi: 10.1097/JTO.0000000000000184.

7.

Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer.

Chang SC, Lai YC, Hung JC, Chang CY.

Medicine (Baltimore). 2019 Feb;98(8):e14463. doi: 10.1097/MD.0000000000014463.

8.
10.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team.

Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.

11.

The effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapy.

Gul K, Mehmet K, Meryem A.

Clin Nutr. 2017 Aug;36(4):1022-1028. doi: 10.1016/j.clnu.2016.06.012. Epub 2016 Jun 23.

PMID:
27373496
12.

How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U.

Clin Lung Cancer. 2015 May;16(3):183-92. doi: 10.1016/j.cllc.2014.08.005. Epub 2014 Nov 13.

13.

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R.

J Clin Oncol. 2005 Apr 1;23(10):2145-54.

PMID:
15800308
14.

[Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].

Wang J, Pang QS, Wang P, Wang J, Wang W.

Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):769-72. Chinese.

PMID:
18396691
15.

Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer.

Wiersma TG, Dahele M, Verbakel WF, van de Ven PM, de Haan PF, Smit EF, van Reij EJ, Slotman BJ, Senan S.

Lung Cancer. 2013 Apr;80(1):62-7. doi: 10.1016/j.lungcan.2013.01.006. Epub 2013 Jan 26.

PMID:
23357464
16.

Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.

Dandekar VK, Young J, Kiel K, Bonomi P, Fidler MJ, Batus M, Sher DJ.

Am J Clin Oncol. 2015 Dec;38(6):605-9. doi: 10.1097/COC.0000000000000007.

PMID:
24781341
17.

Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy.

Zhang Z, Xu J, Zhou T, Yi Y, Li H, Sun H, Huang W, Wang D, Li B, Ying G.

Radiat Oncol. 2014 Feb 15;9:54. doi: 10.1186/1748-717X-9-54.

18.

A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies.

Al-Halabi H, Paetzold P, Sharp GC, Olsen C, Willers H.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):803-10. doi: 10.1016/j.ijrobp.2015.03.018. Epub 2015 Mar 25.

PMID:
26104934
19.

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).

Zehentmayr F, Söhn M, Exeli AK, Wurstbauer K, Tröller A, Deutschmann H, Fastner G, Fussl C, Steininger P, Kranzinger M, Belka C, Studnicka M, Sedlmayer F.

Radiat Oncol. 2015 May 28;10:121. doi: 10.1186/s13014-015-0429-1.

20.

IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.

Landau DB, Hughes L, Baker A, Bates AT, Bayne MC, Counsell N, Garcia-Alonso A, Harden SV, Hicks JD, Hughes SR, Illsley MC, Khan I, Laurence V, Malik Z, Mayles H, Mayles WPM, Miles E, Mohammed N, Ngai Y, Parsons E, Spicer J, Wells P, Wilkinson D, Fenwick JD.

Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1367-1377. doi: 10.1016/j.ijrobp.2016.03.031. Epub 2016 Mar 28.

Supplemental Content

Support Center